AbbVie Inc (ABBV)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	56,334,000	55,533,000	55,000,000	54,403,000	54,318,000	55,138,000	56,023,000	56,741,000	58,054,000	57,819,000	57,349,000	56,725,000	56,197,000	55,169,000	53,729,000	50,195,000	45,804,000	40,650,000	36,227,000	34,057,000
Total assets	US$ in thousands	135,161,000	143,422,000	141,937,000	148,874,000	134,711,000	136,221,000	135,367,000	134,544,000	138,805,000	141,325,000	143,186,000	143,211,000	146,529,000	148,858,000	147,972,000	150,501,000	150,565,000	149,621,000	149,530,000	91,199,000
Total asset turnover		0.42	0.39	0.39	0.37	0.40	0.40	0.41	0.42	0.42	0.41	0.40	0.40	0.38	0.37	0.36	0.33	0.30	0.27	0.24	0.37

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $56,334,000K ÷ $135,161,000K
= 0.42

The total asset turnover ratio of AbbVie Inc has been relatively stable over the period from March 31, 2020, to December 31, 2024, ranging from 0.24 to 0.42. This ratio measures the efficiency of the company in generating revenue from its total assets.

The ratio shows how efficiently AbbVie is utilizing its assets to generate sales. A higher ratio indicates that the company is generating more revenue per dollar of assets, which is generally a positive sign.

The ratio has shown an improving trend, starting from 0.24 in June 2020 and gradually increasing to 0.42 by December 31, 2024. This suggests that AbbVie has been able to increase its revenue relative to its total assets over this period.

Overall, the consistent improvement in total asset turnover indicates that AbbVie Inc has been effectively managing its assets to drive sales growth, which is a positive indicator of operational efficiency and financial performance.